Application of hemopoietin sourced peptide in preparation of medicine for treating metabolic syndrome

A technology of erythropoietin and metabolic syndrome, which is applied in the field of biomedicine to achieve the effect of prolonging the half-life, increasing the route of administration, and reducing the frequency of administration

Active Publication Date: 2015-12-16
ARMY MEDICAL UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] At present, there is no research and patent publication on the application of erythropoietin-derived peptides in metabolic syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hemopoietin sourced peptide in preparation of medicine for treating metabolic syndrome
  • Application of hemopoietin sourced peptide in preparation of medicine for treating metabolic syndrome
  • Application of hemopoietin sourced peptide in preparation of medicine for treating metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Preparation of Erythropoietin-derived Peptides

[0042] The amino acid sequence of the erythropoietin-derived peptide is as follows: GlnGluGlnLeuGluArgAlaLeuAsnSerSer, which is derived from the 58th (glutamine), 62nd (glutamic acid), 65th (glutamine), No. 69 (leucine), No. 72 (glutamic acid), No. 76 (arginine), No. 79 (alanine), No. 80 (leucine), No. 83 (day Paragine), the 84th (serine), the 85th (serine).

[0043] Erythropoietin-derived peptides were synthesized on an ARI431A solid-phase peptide synthesizer (PE, USA). Methods The standard fluorenylmethoxycarbonyl (Fmoc) protocol was used, and arginine was coupled twice. Initially select 0.125mmol p-hydroxymethylphenoxymethyl polystyrene resin (HMP resin), extend the peptide chain from the carboxyl terminal to the amino terminal one by one according to the polypeptide sequence, the amount of each amino acid is 0.5mmol, and the mole of the resin The ratio is 4:1. The α-amino acids of various amino acids are ...

Embodiment 2

[0045] Example 2 Preparation of Erythropoietin-derived Peptide Liposomes

[0046] Erythropoietin-derived peptide liposomes were prepared by reverse evaporation method. Dissolve lecithin and cholesterol in diethyl ether at a mass ratio of 1:1, distill off the organic solvent therein under reduced pressure, and form a uniform W / O emulsion in an ultrasonic water bath for 5 minutes, then add an appropriate amount as shown in SEQ ID NO: 1 The indicated erythropoietin-derived peptides were repeatedly frozen and thawed in a 42°C water bath and dry ice, and passed through a film extruder with a pore size of 100 nm several times. Utilizing that the volume of the erythropoietin-derived peptide shown in SEQ ID NO: 1 becomes larger after being bound to the liposome, the erythropoietin-derived peptide not bound to the liposome is separated with an agarose gel CL-4B column. The mass ratio of lecithin, cholesterol and small molecule polypeptide in the liposome is 50:50:1. Then the morpholo...

Embodiment 3

[0047] Example 3 The effect of erythropoietin-derived peptide and liposomes on obesity, diabetes and hyperlipidemia

[0048] 1. Test animals:

[0049] Wild-type C57 mice, male, 5-6 weeks old, were purchased from the Experimental Animal Center of Daping Hospital, Third Military Medical University, and were normally kept in a clean animal room.

[0050] 2. Drugs and grouping:

[0051] Erythropoietin-derived peptide treatment group: intraperitoneal injection of 30 μg / kg body weight of erythropoietin-derived peptide shown in SEQ ID NO: 1, a total of 18 animals, injected once every other day;

[0052] Erythropoietin-derived peptide liposome treatment group: intraperitoneal injection of 30 μg / kg body weight of erythropoietin-derived peptide liposome, a total of 18, injected once every other day;

[0053] High-fat feeding group: give the same volume of PBS as the treatment group for intraperitoneal injection, a total of 18 animals, and inject once every other day;

[0054] General...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of bio-medicines, and particularly relates to an application of a hemopoietin sourced peptide in preparation of a medicine for treating the metabolic syndrome. The application includes an application of preparation of medicines for treating obesity, diabetes mellitus and hyperlipemia, The hemopoietin sourced peptide can be prepared into lipidosome, and the metabolic syndrome can be treated by the hemopoietin sourced peptide and the hemopoietin sourced peptide lipidosome, the syndromes of the hemopoietin sourced peptide are remarkably relieved after treatment, and the effect of the hemopoietin sourced peptide lipidosome is superior to that of the hemopoietin sourced peptide, and the administration frequency can be reduced. The application of the hemopoietin sourced peptide lipidosome to medicines can be used for prolonging the medicine acting period, increasing the lipid solubility and stability of the medicines and reducing toxic and side effects. Therefore, compared with an independent application of micro-molecule polypeptide, lipidosome coated micro-molecule polypeptide has the advantages of prolonging half-life period, improving stability and lipid solubility and increasing administration routes. The hemopoietin sourced peptide has an important clinical application value.

Description

technical field [0001] The invention belongs to the field of biomedicine, and particularly relates to the application of erythropoietin-derived peptides in the preparation of medicines for treating metabolic syndrome. Background technique [0002] Metabolic syndrome refers to the pathological state of metabolic disorders of proteins, fats, carbohydrates and other substances in the human body. It has the following characteristics: ① A variety of metabolic disorders in one body, including obesity, hyperglycemia, hypertension, dyslipidemia, high blood viscosity, high uric acid, high incidence of fatty liver and hyperinsulinemia, these metabolic disorders are heart, Pathological basis of cerebrovascular disease and diabetes. It can be seen that diabetes is not an isolated disease, but one of the components of metabolic syndrome. ② There is a common pathological basis. At present, it is mostly believed that their common cause is insulin resistance and hyperinsulinemia caused by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P3/00A61P3/04A61P3/06A61P3/10
Inventor 张志仁刘宇其罗邦伟
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap